✦ LIBER ✦

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

✍ Scribed by Allan Lipton; Karim Fizazi; Alison T. Stopeck; David H. Henry; Janet E. Brown; Denise A. Yardley; Gary E. Richardson; Salvatore Siena; Pablo Maroto; Michael Clemens; Boris Bilynskyy; Veena Charu; Philippe Beuzeboc; Michael Rader; Maria Viniegra; Fred Saad; Chunlei Ke; Ada Braun; Susie Jun

Book ID: 116431139
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 612 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2012.08.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Re: Superiority of denosumab to zoledron

Re: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of three pivotal, randomised, phase 3 trials

✍ Araki, Kazuhiro; Ito, Yoshinori; Takahashi, Shunji 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 193 KB

3061 POSTER Prevention of Skeletal-Relat

3061 POSTER Prevention of Skeletal-Related Events With Denosumab or Zoledronic Acid – Combined Analysis From 3 Registrational Trials

✍ A. Lipton; K. Fizazi; A.T. Stopeck; D.H. Henry; J.E. Brown; F. Saad; D. Yardley; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Interpreting results from oncology clini

Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients

✍ George Dranitsaris, Eleftheria Hatzimichael 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 164 KB

AOS13 Denosumab versus zoledronic acid f

AOS13 Denosumab versus zoledronic acid for the prevention of skeletal-related events in patients with bone metastases secondary to solid tumours: An integrated analysis of three phase 3 studies

✍ A.T. Stopeck; G. Richardson; S. Siena; A. Lipton; J. Brown; K. Fizazi; D. Henry; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Delaying skeletal-related events in a ra

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

✍ Henry, David; Vadhan-Raj, Saroj; Hirsh, Vera; Moos, Roger; Hungria, Vania; Costa 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 315 KB

Denosumab versus zoledronic acid (ZA) fo

Denosumab versus zoledronic acid (ZA) for the treatment of bone metastases: An integrated analysis of results from 2 randomized, double-blind, phase 3 trials

✍ A. Lipton*; A. Stopeck; R. von Moos; D. Henry; G. Richardson; G. Rodriguez; H. B 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 48 KB